Full Agonists and Maximal Response

A full agonist is a ligand that, on binding to a receptor, produces the largest effect the system is capable of — the maximal response, or Emax. Full agonists are defined relative to the tissue or system in which they act, and the concept of receptor reserve explains how a full agonist can reach maximal response while occupying only a fraction of the available receptors.

Definition

A full agonist is a ligand that produces the maximal response a given receptor system can generate (its Emax), reflecting an intrinsic efficacy high enough that, with available receptor reserve, full activation is achieved without full receptor occupancy.

Scope

This topic covers the definition of a full agonist, the maximal-response (Emax) parameter, the distinction between agonist potency and maximal effect, and the related ideas of intrinsic efficacy, receptor reserve, and spare receptors. It is a methodological reference within pharmacodynamics and does not address drug selection or dosing.

Core questions

• What makes an agonist 'full' rather than partial in a given tissue?
• How does maximal response (Emax) differ from potency (EC50)?
• How does receptor reserve allow a full agonist to reach Emax below full occupancy?
• Why is the full-agonist label system-dependent rather than an absolute property of a drug?

Key concepts

• Maximal response (Emax)
• Intrinsic efficacy
• Potency (EC50) versus maximal effect
• Receptor reserve / spare receptors
• Concentration-response curve
• System dependence of the full-agonist label

Key theories

Operational (Black-Leff) model

Expresses the agonist concentration-response curve in terms of binding affinity and an efficacy parameter (transducer ratio); a high transducer ratio describes a full agonist that reaches the system maximum, and explains why high-efficacy agonists need only partial occupancy.

Mechanisms

A full agonist combines sufficient affinity to bind the receptor with sufficient efficacy to drive the receptor through its activation step and engage the downstream signalling machinery to the system's limit. Where signal amplification is large, only a fraction of receptors need be occupied to elicit the maximal response, leaving a receptor reserve (spare receptors); this is why a full agonist's concentration for half-maximal response (EC50) can lie well to the left of its half-maximal occupancy. The operational model captures this by separating the affinity term from an efficacy term, so that a sufficiently high efficacy yields a curve that saturates at the tissue Emax regardless of further increases in efficacy. Because amplification and receptor number vary between tissues, the same drug may behave as a full agonist in one system and only a partial agonist in another.

Clinical relevance

Distinguishing maximal efficacy from potency is central to interpreting how drug classes are described and compared, and the existence of receptor reserve explains observations such as preserved responses after partial receptor loss or blockade. This entry is reference material on how agonist action is quantified and classified; it is not a basis for individual treatment or dosing decisions.

Evidence & guidelines

The definitions of agonist, full agonist, efficacy, and the EC50/Emax parameters used here follow the IUPHAR recommendations on terms and symbols in quantitative pharmacology.

History

The notion that agonists differ in their maximal effect was sharpened by Ariens' and Stephenson's mid-century work on intrinsic activity and efficacy, and by the recognition of spare receptors in amplified systems. The operational model of Black and Leff (1983) provided a quantitative framework in which full agonism corresponds to a high transducer ratio, allowing maximal response and potency to be treated as separable parameters.

Key figures

• James W. Black
• Paul Leff
• David Colquhoun
• Terry Kenakin

Seminal works

• black-leff-1983
• colquhoun-1998
• neubig-2003

Frequently asked questions

What is the difference between a full agonist's potency and its maximal effect?

Maximal effect (Emax) is how large a response the agonist can ultimately produce, while potency (EC50) is the concentration needed to reach half of that response. Two full agonists can share the same Emax yet differ greatly in potency.

How can a full agonist produce a maximal response without occupying all receptors?

In tissues with signal amplification there is a receptor reserve, or spare receptors, so a high-efficacy agonist reaches the maximal response while occupying only a fraction of the receptors present.